Companies:
49,638
Total Market Cap:
134075337934734.49
Global Rank
#1794
Country Rank
#225
Market Cap
10.75 B
Price
11.82
Change (%)
1.33%
Volume
1.1 M
Akeso's latest marketcap:
10.75 B
As of 06/18/2025, Akeso's market capitalization has reached $10.75 B. According to our data, Akeso is the 1794th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 10.75 B |
| Revenue (ttm) | 287.82 M |
| Net Income (ttm) | -69,722,802.3 |
| Shares Out | 897.58 M |
| EPS (ttm) | -0.08 |
| Forward PE | 993.02 |
| Ex-Dividend Date | n/a |
| Earnings Date | 05/28/2025 |
Market Cap Chart
Data Updated: 06/18/2025
Akeso's yearly market capitalization.
Akeso has seen its market value drop from HK$29.91 B to HK$10.75 B since 2020, representing a total decrease of 64.06% and an annual compound decline rate (CAGR) of 20.49%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/18/2025 | HK$10.75 B | 54.94% | 1794 |
| 12/31/2024 | HK$54.48 B | 39.61% | 2301 |
| 12/29/2023 | HK$39.03 B | 7.91% | 2870 |
| 12/30/2022 | HK$36.17 B | 30.19% | 2865 |
| 12/31/2021 | HK$27.78 B | -7.12% | 4189 |
| 12/31/2020 | HK$29.91 B | 3468 |
Company Profile
Akeso, Inc. Overview
Akeso, Inc. is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of innovative antibody drugs.
Key Product Pipeline
- AK104 – A PD-1/CTLA-4 bi-specific antibody targeting cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors.
- AK112 – A PD-1/VEGF bi-specific antibody for NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors.
- AK117 – A CD47 monoclonal antibody for myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma.
- AK105 – A PD-1 monoclonal antibody targeting classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma, thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumors.
- AK119 – A CD73 monoclonal antibody for solid tumors and NSCLC.
- AK109 – A VEGFR-2 monoclonal antibody for GC, GEJ, NSCLC, HCC, and solid tumors.
- AK102 – A PCSK9 monoclonal antibody for hypercholesterolemia and mixed hyperlipidemia.
- AK101 – An IL-12/IL-23 monoclonal antibody for moderate-to-severe psoriasis and ulcerative colitis.
- AK111 – An IL-17 monoclonal antibody for moderate-to-severe psoriasis and ankylosing spondylitis.
- AK120 – An IL-4R monoclonal antibody for moderate-to-severe atopic dermatitis.
Preclinical Development
- AK127 – A TIGIT monoclonal antibody for solid tumors.
- AK115 – A NGF monoclonal antibody.
Strategic Collaborations
Akeso has established partnerships with leading pharmaceutical companies, including:
- Pfizer Pharmaceuticals
- AstraZeneca Pharmaceuticals
- Summit Therapeutics Inc.
- Shenzhen Chipscreen Biosciences Co., Ltd.
Company Background
Founded in 2012, Akeso, Inc. is headquartered in Zhongshan, the People’s Republic of China.
Frequently Asked Questions
-
What is Akeso's (HKG-9926) current market cap?As of 06/18/2025, Akeso (including the parent company, if applicable) has an estimated market capitalization of $10.75 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Akeso (HKG-9926) rank globally by market cap?Akeso global market capitalization ranking is approximately 1794 as of 06/18/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.